Literature DB >> 9545154

Rifampin, a useful drug for nonmycobacterial infections.

J J Vesely1, F D Pien, B C Pien.   

Abstract

Rifampin has clinical efficacy against a wide variety of organisms, including Staphylococcus aureus, Legionella pneumophila, group A Streptococcus, Brucella sp, Haemophilus influenzae, and Neisseria meningitidis, as well as in vitro activity against penicillin-resistant Streptococcus pneumoniae, Neisseria gonorrhoeae, Chlamydia trachomatis, Haemophilus ducreyi, and many gram-negative rods. Rifampin is a useful drug for several types of bacterial infections because of its broad spectrum of activity, excellent tissue penetration, and low side effect profile. In combination with other antibiotics, it may be effective when conventional therapies are not.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9545154

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

1.  Legionnaires' Disease in South Africa, 2012-2014.

Authors:  Nicole Wolter; Maimuna Carrim; Cheryl Cohen; Stefano Tempia; Sibongile Walaza; Philip Sahr; Linda de Gouveia; Florette Treurnicht; Orienka Hellferscee; Adam L Cohen; Alvaro J Benitez; Halima Dawood; Ebrahim Variava; Jonas M Winchell; Anne von Gottberg
Journal:  Emerg Infect Dis       Date:  2016-01       Impact factor: 6.883

2.  Molecular basis of rifampin resistance in Streptococcus pneumoniae.

Authors:  T Padayachee; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.

Authors:  Brian J Morrow; Darren Abbanat; Ellen Z Baum; Steven M Crespo-Carbone; Todd A Davies; Wenping He; Wenchi Shang; Anne Marie Queenan; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

4.  Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus.

Authors:  David J Riedel; Elizabeth Weekes; Graeme N Forrest
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

Review 5.  Perioperative pharmacotherapy in patients with left ventricular assist devices.

Authors:  Nicholas C Dang; Yoshifumi Naka
Journal:  Drugs Aging       Date:  2004       Impact factor: 4.271

6.  Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations.

Authors:  E Fiaux; M Titecat; O Robineau; J Lora-Tamayo; Y El Samad; M Etienne; N Frebourg; N Blondiaux; B Brunschweiler; F Dujardin; E Beltrand; C Loiez; V Cattoir; J P Canarelli; C Hulet; M Valette; S Nguyen; F Caron; H Migaud; E Senneville
Journal:  BMC Infect Dis       Date:  2016-10-13       Impact factor: 3.090

7.  Early specific host response associated with starting effective tuberculosis treatment in an infection controlled placebo controlled mouse study.

Authors:  Alice L den Hertog; Alex F de Vos; Paul R Klatser; Richard M Anthony
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

8.  Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Authors:  Richard E Kast; Nicolas Skuli; Georg Karpel-Massler; Guido Frosina; Timothy Ryken; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2017-06-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.